In vitro antiviral activity of SCH446211 (SCH6), a novel inhibitor of the hepatitis C virus NS3 serine protease | Zendy

Rong Liu | Zendy; Karim Abid | Zendy; John Pichardo | Zendy; Valerio Pazienza | Zendy; Paul Ingravallo | Zendy; Rong Kong | Zendy; Sudhir Agrawal | Zendy; S.F. Bogen | Zendy; A. K. SAKSENA | Zendy; Kui Cheng | Zendy; Andrew Prongay | Zendy; F. George Njoroge | Zendy; Bahige M. Baroudy | Zendy; Francesco Negro | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In vitro antiviral activity of SCH446211 (SCH6), a novel inhibitor of the hepatitis C virus NS3 serine protease

Author(s) -

Rong Liu,

Karim Abid,

John Pichardo,

Valerio Pazienza,

Paul Ingravallo,

Rong Kong,

Sudhir Agrawal,

S.F. Bogen,

A. K. SAKSENA,

Kui Cheng,

Andrew Prongay,

F. George Njoroge,

Bahige M. Baroudy,

Francesco Negro

Publication year - 2006

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkl455

Subject(s) - ns3 , serine protease , hepatitis c virus , ns2 3 protease , protease inhibitor (pharmacology) , in vitro , protease , virology , hepacivirus , virus , serine , medicine , chemistry , biology , pharmacology , enzyme , biochemistry , viral load , antiretroviral therapy

Current hepatitis C virus (HCV) therapies may cure approximately 60% of infections. They are often contraindicated or poorly tolerated, underscoring the need for safer and more effective drugs. A novel, alpha-ketoamide-derived, substrate-based inhibitor of the HCV serine protease (SCH446211) was developed. Compared with earlier reported inhibitors of similar chemical class, it has a P1'-P2' extension which provides extended interaction with the protease active site. The aim of this study was to evaluate the in vitro antiviral activity of SCH446211.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research